Comparisons

Victoza vs. Ozempic: Comparing Liraglutide and Semaglutide for Weight Loss and Diabetes

GLP-1 Companion · 9 min read

Quick answer

Victoza (liraglutide) was the first widely used GLP-1 medication, but Ozempic (semaglutide) has largely overshadowed it. This comparison breaks down the clinical data, key differences, and how to decide between them with your doctor.

Victoza (liraglutide) and Ozempic (semaglutide) are both GLP-1 receptor agonists — injectable medications that mimic the gut hormone GLP-1 to reduce appetite, slow gastric emptying, and improve blood sugar control. Victoza was among the first widely adopted GLP-1 medications, approved by the FDA for type 2 diabetes in 2010 and for cardiovascular risk reduction in 2017. Ozempic (once-weekly semaglutide) received FDA approval for type 2 diabetes in 2017 and has since become the dominant brand in the class. This article compares the two head-to-head.

Mechanism of Action: Both Are GLP-1 Receptor Agonists

Both liraglutide (Victoza) and semaglutide (Ozempic) work by binding to and activating the GLP-1 receptor. They produce the same fundamental effects:

Stimulate insulin secretion in a glucose-dependent manner (lowering post-meal blood sugar)
Suppress glucagon release (preventing excess glucose release from the liver)
Slow gastric emptying (producing prolonged satiety)
Reduce appetite through hypothalamic signaling

The key structural difference is that semaglutide has been engineered with a modified fatty acid chain that binds more strongly to albumin in the bloodstream, giving it a much longer half-life. This is why Victoza requires daily injections while Ozempic is injected only once per week.

Dosing and Administration

Victoza (liraglutide): Injected once daily via subcutaneous pen. Starting dose is 0.6 mg/day for the first week, then 1.2 mg/day, with an option to increase to 1.8 mg/day for additional glycemic benefit.
Ozempic (semaglutide): Injected once weekly via subcutaneous pen. Starting dose is 0.25 mg/week for 4 weeks, then 0.5 mg/week; can be increased to 1 mg/week and 2 mg/week based on clinical response.

Weight Loss: Semaglutide Wins Decisively

Clinical trials have consistently shown that semaglutide produces greater weight loss than liraglutide, both in diabetes and obesity populations.

Victoza (liraglutide 1.8 mg) in LEADER trial: Average weight loss of approximately 2.3 kg (5 lbs) over 3.5 years in patients with type 2 diabetes.
Saxenda (liraglutide 3.0 mg, the obesity-approved dose) in SCALE trial: Average weight loss of 8.0 kg (17.6 lbs) or about 8% of body weight at 56 weeks in patients with obesity.
Ozempic (semaglutide 1.0 mg) in SUSTAIN-6: Average weight loss of approximately 4.5 kg (9.9 lbs) over 104 weeks in patients with type 2 diabetes.
Ozempic at 2 mg (highest approved dose for diabetes) produces meaningfully greater weight loss than 1 mg, though less than Wegovy.
Wegovy (semaglutide 2.4 mg, the obesity-approved dose) in STEP 1: Average weight loss of 14.9% of body weight over 68 weeks.

When comparing equivalent indications (diabetes-approved doses), semaglutide produces roughly 2–3× more weight loss than liraglutide at equivalent treatment durations. This is the primary reason Ozempic has largely replaced Victoza in clinical practice.

Blood Sugar (HbA1c) Reduction

Both medications effectively lower HbA1c, but semaglutide generally produces larger reductions:

Victoza (liraglutide 1.8 mg): Typically reduces HbA1c by 1.0–1.5 percentage points in clinical trials.
Ozempic (semaglutide 1.0 mg): Typically reduces HbA1c by 1.5–1.8 percentage points.
Ozempic (semaglutide 2.0 mg): Reduces HbA1c by approximately 1.8–2.0 percentage points.

Cardiovascular Outcomes

Both medications have demonstrated cardiovascular benefits in landmark outcome trials:

Victoza — LEADER trial (2016): A 13% reduction in the composite of cardiovascular death, non-fatal MI, and non-fatal stroke vs. placebo in patients with type 2 diabetes and established or high-risk cardiovascular disease. This was driven primarily by a reduction in cardiovascular mortality.
Ozempic — SUSTAIN-6 trial (2016): A 26% reduction in the composite cardiovascular endpoint. However, SUSTAIN-6 was a relatively small trial designed for regulatory non-inferiority — the result should be interpreted cautiously.
Semaglutide — SELECT trial (2023): A 20% reduction in MACE in adults with obesity (no diabetes requirement) and established cardiovascular disease. This is the strongest cardiovascular outcome trial for either medication.

Side Effects: Similar Profiles, Slightly Different Tolerability

Both medications share a similar GI side-effect profile: nausea, vomiting, diarrhea, constipation, and abdominal pain. These are most prominent during dose escalation and typically improve over time.

Nausea: Common with both; roughly 20–25% of patients during dose escalation.
Discontinuation due to GI side effects: ~5–8% for both medications in clinical trials.
Injection site reactions: Generally mild for both; no major differences.
Both carry a boxed warning for thyroid C-cell tumor risk (based on animal data) and contraindication in patients with personal/family history of medullary thyroid carcinoma or MEN2.
Both are contraindicated in pregnancy.

Cost and Availability

Victoza (liraglutide): List price approximately $900–$1,200/month. A generic liraglutide injection launched in the US in mid-2025, significantly reducing cost for some patients.
Ozempic (semaglutide): List price approximately $935–$1,350/month. No generic currently available in the US.
Insurance coverage: Both are widely covered for type 2 diabetes indications. Victoza's lower cost (with generic) may make it more accessible for cash-pay patients in 2025–2026.

Which Should You Choose?

For most patients, Ozempic (semaglutide) offers superior weight loss, better glycemic control, once-weekly dosing convenience, and strong cardiovascular outcome data. It is the preferred option in most clinical guidelines. However, Victoza (liraglutide) may be preferable in specific circumstances:

Cost: With generic liraglutide now available, it may be significantly cheaper for patients without insurance coverage.
Dose flexibility: Daily dosing allows for fine-grained dose adjustments that weekly injections cannot offer.
History of use: Some patients have been stable on Victoza for years and have no clinical reason to switch.
Tolerability: A small number of patients tolerate liraglutide better than semaglutide; no medication is universally preferred.

The Bottom Line

Victoza and Ozempic are both effective GLP-1 receptor agonists, but semaglutide has emerged as the clinical and commercial leader due to its greater weight loss efficacy, superior glycemic control, once-weekly dosing, and strong cardiovascular evidence. The arrival of generic liraglutide has created a new cost-accessibility angle for Victoza. The right choice depends on your health profile, insurance, and goals — a conversation best had with your healthcare provider.